Not all firms think alike though. When it comes to sharing IP, pharma firms are quite divided on the matter. There have been voluntary licenses from firms such as US-based AbbVie, which has suspended its global patent rights for Kaletra, an HIV drug that has been identified as a potential treatment for the coronavirus. Similarly, Gilead Sciences, Inc, an American biopharmaceutical company, has signed nonexclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in Egypt, India and Pakistan to further expand supply of remdesivir, its antiviral drug used for the treatment of COVID-19.
Labrador Diagnostics, an American company, has also offered to grant royalty-free licenses to third parties to use its patented diagnostics technology for use in tests directed to COVID-19. Swiss firm Roche, has also recently released details of a formulation used in testing kits for the virus, following a plea from the Dutch government, according to reports. Pharma firms have been collaborating with each other, sharing expertise and technologies. Most of the firms are also part of the World Health Organization (WHO’s) COVID-19 Tools Accelerator, which brings together many different organizations to speed-up drug development.
However, most of the big pharma firms have pushed back against waiving IP rights as well as the concept of patent pool, as they feel it hampers innovation.
The WHO announced on May 29, 2020, the COVID-19 Technology Access Pool (C-TAP) that will compile, in one place, pledges of commitment made under the Solidarity Call to Action to voluntarily share COVID-19 health technology-related knowledge, intellectual property and data. Most of the developing countries such as Indonesia, Malaysia, Bangladesh, etc. have joined the WHO’s Solidarity Call to Action. However, none of the pharma firms have joined the initiative as yet.
This story is from the BioSpectrum Asia September 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia September 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.